- Conditions
- Primary Hyperoxaluria
- Interventions
- DCR-PHXC, Placebo
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 833
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postoperative Nausea and Vomiting (PONV)
- Interventions
- TAK-951, Ondansetron, Ondansetron Placebo, TAK-951 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Pasadena, California • Tamarac, Florida + 4 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Ixekizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more
- Conditions
- Healthy Volunteer
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid, 5-FU, Placebo for ASP2138, Placebo for Pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Saint Louis Park, Minnesota
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- Efinopegdutide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
- Conditions
- Pruritus
- Interventions
- Dupilumab, Placebo, Fexofenadine (loratadine if not available)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Bakersfield, California • La Jolla, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Non-diabetic Overweight or Obese
- Interventions
- Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
- Drug
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Asthma
- Interventions
- AMG 691, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 15
- States / cities
- Lake Forest, California • Aventura, Florida • Palmetto Bay, Florida + 12 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- Psoriasis
- Interventions
- Placebo for Risankizumab, Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
- Conditions
- Cachexia
- Interventions
- AV-380, Placebo
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Hypercholesterolemia
- Interventions
- AZD8233
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Human Immuno-deficiency Virus (HIV) Disease
- Interventions
- Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
- Conditions
- Moderately to Severely Active Ulcerative Colitis
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cordova, Tennessee
- Conditions
- Diabetic Nephropathy
- Interventions
- Repository Corticotropin Injection, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 10
- States / cities
- Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
- Conditions
- Post-Traumatic Headache
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab 162 mg, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Izokibep, Placebo to izokibep
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 40
- States / cities
- Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
- Conditions
- Healthy Participants
- Interventions
- Lu AG22515, Placebo, Immune System Activator
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Long Beach, California • Secaucus, New Jersey
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- ALN-KHK, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Vista, California • Lake Worth, Florida + 8 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
- Conditions
- Femur Neck Fracture
- Interventions
- Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
- Drug · Dietary Supplement
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 19
- States / cities
- San Diego, California • Golden, Colorado • Washington D.C., District of Columbia + 16 more